Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

Summary

This is a double blind placebo controlled trial in Parkinson's disease (PD) patients with neurogenic orthostatic hypotension (NOH). Investigators hypothesize that the study drug (droxidopa) may improve cerebral perfusion more robustly than systemic BP, possibly by direct action within the CNS vasculature. This study is designed to determine if droxidopa improves cerebral perfusion measures in PD patients with NOH, in addition to peripheral BP measures and subjective responses.

Timeline

Start

2018-08-23

Primary completion

2022-02-02

Completion

2022-02-02

Drugs

Indications